| Autor: |
Marx, A., Schmitz, J.L., Gay, C.L., Kim, M.K., Rimland, C.A., Swygard, H., Bramson, B., Fischer, W.A., Eron, J.J., Napravnik, S., Carson, S.S., Parr, J.B., Morgan, C.E., Bell, G.J., Hedrick, T. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| DOI: |
10.17615/135q-kz12 |
| Popis: |
The interleukin-6 receptor antagonist tocilizumab became widely used early in the coronavirus disease 2019 (COVID-19) pandemic based on small observational studies that suggested clinical benefit in COVID-19 patients with a hyperinflammatory state. To inform our local treatment algorithms in the absence of randomized clinical trial results, we performed a rapid analysis of the first 11 hospitalized COVID-19 patients treated with tocilizumab at our academic medical center. We report their early clinical outcomes and describe the process by which we assembled a team of diverse trainees and stakeholders to extract, analyze, and disseminate data during a time of clinical uncertainty. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
